(A joint stock company incorporated in the People's Republic of China with limited liability) Stock Code: 1513
e | |
r | |
u | |
t | |
u | |
F | |
t | |
h | |
g | |
i | |
r | |
B |
&
m o d is W
,
e
f i
L
n e e r g r evE
2023
INTERIM
REPORT
*
CONTENTS
List of Documents Available for Inspection | 2 |
Financial Highlights | 3 |
Section I | |
Important Notice and Definitions | 5 |
Section II | |
Company Profile and Major Financial Indicators | 11 |
Section III | |
Management Discussion and Analysis | 16 |
Section IV | |
Corporate Governance | 93 |
Section V | |
Environmental and Social Responsibility | 98 |
Section VI | |
Major Events | 132 |
Section VII | |
Changes In Equity and Shareholders | 156 |
Section VIII | |
Information on Preferred Shares | 167 |
Section IX | |
Information on Bonds | 168 |
Section X | |
Financial Report | 169 |
LIST OF DOCUMENTS AVAILABLE FOR INSPECTION
- Full text of the 2023 Interim Report of the Company signed by the legal representative.
- The unaudited financial report for the six months ended 30 June 2023 of the Company prepared in accordance with the China Accounting Standards for Business Enterprises, which has been signed and sealed by the person-in-charge of the Company, the person-in-charge of the Company's accounting work and the person-in-charge of the accounting department (the head of the accounting department).
- The original copies of all documents and announcements of the Company which have been disclosed to the public on the website designated by the CSRC during the Reporting Period.
(IV) | The English and Chinese versions of the 2023 Interim Report of the Company published on the website of the |
Hong Kong Exchanges and Clearing Limited. |
2 | Livzon Pharmaceutical Group Inc. Interim Report 2023 |
FINANCIAL HIGHLIGHTS
Major financial indicators (RMB in millions) | |||
6.15% | Same Period | ||
Last Year | |||
6,302.57 6,689.92 | |||
Reporting Period | |||
11.50% | 4.52% | -13.96% | 7.62% | ||||
1,426.39 | 1,423.37 | ||||||
1,017.55 | 1,134.57 | 1,046.42 | 1,093.71 | 1,227.31 | 1,322.57 | ||
Operating income | Net profit attributable | Net profit after | Net cash flow from | Total profit | |||
to shareholders of | extraordinary gains or | operating activities | |||||
the Company | losses attributable to | ||||||
shareholders of | |||||||
the Company |
Basic earnings per share (RMB/share)
11.93%
1.09 | 1.22 |
Diluted earnings per share (RMB/share)
Same Period
Last Year
11.93% | Reporting Period | |
1.09 | 1.22 |
Composition of operating income (RMB in millions)
4.45% | 0.94% | Chemical drug preparations | |||||||||
297.99 | 62.70 | ||||||||||
1.70% | APIs and intermediates | ||||||||||
113.41 | Traditional Chinese | ||||||||||
14.26% | medicine preparations | ||||||||||
953.85 | Biological products | ||||||||||
Total Operating | Diagnostic reagents | ||||||||||
and equipment | |||||||||||
Income | |||||||||||
52.02% | Others | ||||||||||
1,781.67 | 6,689.92 | 3,480.29 | |||||||||
26.63% |
Livzon Pharmaceutical Group Inc. Interim Report 2023 | 3 |
FINANCIAL HIGHLIGHTS
PERFORMANCE FOR THE REPORTING PERIOD IN TERMS OF REVENUE FROM VARIOUS SECTORS
Unit: RMB in millions
Chemical drug preparations
-7.75%
1,761.50
1,625.05
2.71%
1,340.201,376.48
5.31% | |||||||
2.11% | |||||||
264.00 | 278.03 | ||||||
194.65 | 198.76 | ||||||
2022 | 2023 | 2022 | 2023 | 2022 | 2023 | 2022 | 2023 |
Gastroenterology | Gonadotropic | Psychiatry | Anti-infection | ||||
hormones | |||||||
APIs and | Traditional Chinese | |
intermediates | medicine preparations | |
3.03% | ||
1,729.34 | 1,781.67 |
953.85
94.42%
490.62
Biological products
5.93%
107.06 113.41
Diagnostic reagents
and equipment
-13.88%
346.04
297.99
2022 | 2023 | 2022 | 2023 | 2022 | 2023 | 2022 | 2023 |
4 | Livzon Pharmaceutical Group Inc. Interim Report 2023 |